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Abstract
One of the most promising avenues for interpreting large datasets of molecular expression profiles involves pathway-based analysis. 
Pathways are collection of genes and proteins that perform a well-defined biological task. These pathways have been established through 
decades of molecular biology research and are collected in a variety of public pathway repositories (KEGG and Reactome Pathway data-
base). Understanding the complexity of these pathways is critical for understanding normal biological conditions and disease states and 
also since the number of known pathways within the cells is significantly smaller than the number of genes that is typically profiled, the 
transformation of data from a gene-centric view to a pathway-centred one represents a dramatic reduction in the number of dimensions. 
Such reduction allows a biologist to interpret and understand the data in a manner that is not possible when it is viewed as a collection of 
individual genes.
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Introduction
Gene expression studies are used as an independent predictive method for prognosis. In cancer genomic studies, tremendous effort has 
been devoted to pathway-based analysis. Pathway analysis is a promising tool to identify the mechanisms that underlie disease, adaptive 
physiological compensatory responses and new avenues for investigation. Different pathways have different biological functions. Thus, 
it is reasonable to study each pathway separately. Among the many pathways, only a few have predictive power for cancer development. 
Among genes within predictive pathways, there are subsets having small to moderate predictive power, whereas the remaining are noisy 
genes [1￿6].
Background
Genes have the inherent pathway structure, where pathways are composed of multiple genes with coordinated functions. The aim of this 
study was to identify genetic signatures associated with disease prognosis in bladder cancer with respect to hsa05219 pathway obtained 
from Kyoto Encyclopedia of Genes and Genomes (KEGG).
Methods
Microarray data files were taken from Gene Expression Omnibus (GEO), accession number GSE7476. Four different types of data 
files were generated from GSE7476 experiment by analyzing gene expression profiles in normal bladder tissues (controls), low grade 
superficial tumour samples (pathologically classified as Ta low grade, named as Ta), high grade superficial tumours with an unclear 
clinical behaviour (T1 high grade, named as T1) and high grade muscle invasive tumours (pathologically classified as T2, T3 or T4, 
named as T2+).
Data files representing controls and high grade invasive tumours (T2+) were compared for the current review work.
Affymetrix data files
Affymetrix gene expression chip was used for their study and the intensity values seen in the data file were log transformed values. One 
would subtract the control value from the experimental value to find the significant change in expression level. ￿Researchers generally￿ use 
a cut off at least 2-fold change (linear value) between control and experiment to ￿screen significantly differentially expressed genes￿.
Affymetrix does not have a certain threshold cut off that it recommends. Researchers in the community have seemed to adopt a value of 
about 100 (linear) so ~6.65 (log). However, this does not mean that a value of 6.8 is expressed in a sample; this is just a general guide-
line that many researchers have adopted to filter out a bulk of the probe sets. Most researchers will first analyze the data based on fold 
change, then filter on intensity when a probe set is <100 in both samples. A change from 3.5 to 4.8 in a sample could very well be just a 
background, where as a change from 6.0 to 7.4 might be real.
hsa05219 pathway
Pathway hsa05219 referring to bladder cancer was selected from KEGG pathway database (section 6.1 cancers http://www.genome.jp/
kegg/pathway.html). There are totally 42 genes listed in hsa05219 pathway which are believed to be involved in causing bladder cancer 
(Tables 1￿3).www.ecancermedicalscience.com 3
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Sl no. Affy ID Gene name Gene ID
12 0 1 1 0 9 _ s _ a t THBS1 7057
22 0 4 6 3 3 _ s _ a t RPS6KA5 9252
32 0 2 2 8 4 _ s _ a t CDKN1A 1026
42 0 9 9 4 6 _ a t VEGFC 7424
52 0 2 4 3 1 _ s _ a t MYC 4609
62 0 4 3 4 6 _ s _ a t RASSF1 11186
72 0 3 6 8 3 _ s _ a t VEGFB 7423
82 2 4 6 2 1 _ a t MAPK1 5594
92 0 6 7 4 2 _ a t FIGF 2277
10 243829_at BRAF 673
11 212046_x_at MAPK3 5595
12 206324_s_at DAPK2 23604
13 215179_x_at PGF 5228
14 1566678_at MMP2 4313
15 206254_at EGF 1950
16 203132_at RB1 5925
17 212983_at HRAS 3265
18 201895_at ARAF 369
19 202424_at MAP2K2 5605
20 203891_s_at DAPK3 1613
21 211506_s_at IL8 3576
22 201244_s_at RAF1 5894
23 202670_at MAP2K1 5604
24 204947_at E2F1 1869
25 203936_s_at MMP9 4318
26 211607_x_at EGFR 1956
27 228361_at E2F2 1870
28 202246_s_at CDK4 1019
29 202647_s_at NRAS 4893
30 225160_x_at MDM2 4193
31 216836_s_at ERBB2 2064
32 204858_s_at TYMP 1890
33 201131_s_at CDH1 999
34 211300_s_at TP53 7157
35 203139_at DAPK1 1612
36 208712_at CCND1 595
37 204379_s_at FGFR3 2261
38 214352_s_at KRAS 3845
39 203693_s_at E2F3 1871
40 209644_x_at CDKN2A 1029
41 211527_x_at VEGFA 7422
42 204475_at MMP1 4312
Table 1: Gene list from hsa05219 pathway showing affymetrix ID, gene name, and gene IDecancer 2011, 5:189
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Table 2: Displaying affymetrix grades and ID along with T2+ and control mean values
Sl no. Affy grades Affy ID T2+ average C average Difference
1 A 201109_s_at 7.197941667 9.268797667 −2.070856
2A 2 0 4 6 3 3 _ s _ a t 5 . 5 3 8 6 9 8 6 . 9 7 4 2 2 7 6 6 7 −1.435529667
3 A 202284_s_at 8.292146333 9.426557667 −1.134411333
4 A 209946_at 4.972374667 5.932246333 −0.959871667
5 A 202431_s_at 9.570811333 10.20563933 −0.634828
6A 2 0 4 3 4 6 _ s _ a t 5 . 6 8 0 4 9 6 . 3 0 0 8 2 9 6 6 7 −0.620339667
7 A 203683_s_at 4.670015333 5.256459 −0.586443667
8 A 224621_at 8.188972333 8.710883 −0.521910667
9 A 206742_at 3.331917667 3.622964 −0.291046333
10 A 243829_at 5.140807 5.374049333 −0.233242333
11 A 212046_x_at 7.135151667 7.303775667 −0.168624
12 A 206324_s_at 4.684244667 4.824944667 −0.1407
13 A 215179_x_at 7.105821667 7.123966 −0.018144333
14 A 1566678_at 3.752619667 3.757442667 −0.004823
15 A 206254_at 3.159667333 3.112292333 0.047375
16 A 203132_at 6.140205333 6.082435667 0.057769667
17 A 212983_at 6.390220333 6.299536 0.090684333
18 A 201895_at 7.477000333 7.315159 0.161841333
19 A 202424_at 8.049549333 7.880261667 0.169287667
20 A 203891_s_at 6.282708 6.019414667 0.263293333
21 A 211506_s_at 7.225747667 6.952306667 0.273441
22 A 201244_s_at 8.239435333 7.863649667 0.375785667
23 A 202670_at 7.602015 7.090296333 0.511718667
24 A 204947_at 5.903176333 5.286578333 0.616598
25 A 203936_s_at 6.152433667 5.477768667 0.674665
26 A 211607_x_at 5.508033333 4.786028667 0.722004667
27 A 228361_at 5.898566667 5.131460667 0.767106
28 A 202246_s_at 8.944539333 8.051693 0.892846333
29 A 202647_s_at 6.692538 5.796430333 0.896107667
30 A 225160_x_at 7.044023333 6.121776667 0.922246667
31 A 216836_s_at 9.437352333 8.389638667 1.047713667
32 A 204858_s_at 6.671381333 5.556419 1.114962333
33 A 201131_s_at 10.37200433 9.242416333 1.129588
34 A 211300_s_at 5.945064333 4.792846667 1.152217667
35 A 203139_at 8.916442667 7.673051333 1.243391333
36 A 208712_at 8.620222333 7.024218667 1.596003667
37 A 204379_s_at 9.858403 8.250372333 1.608030667
38 A 214352_s_at 9.427273667 7.638116667 1.789157
39 A 203693_s_at 7.203678333 5.31342 1.890258333
40 A 209644_x_at 7.779116333 5.662257333 2.116859
41 A 211527_x_at 8.164427333 6.013361333 2.151066
42 A 204475_at 8.622475667 4.105322667 4.517153
Log difference between the control and study subjects which exceeds more than 1.0 or less than −1.0 were first 
screened. Downregulated genes are marked in green and upregulated genes are marked in red with respect to 
tumour samples.www.ecancermedicalscience.com 5
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Conclusion
We have taken the list of genes associated with bladder cancer pathway from KEGG database. Log difference between the control and 
study subjects which exceeds more than 1.0 or less than −1.0 were first screened. THBS1, RPS6KA5 and CDKN1A are the genes which 
are highly expressed in control when compared with study subjects (T2+). These genes are associated with ￿angiogenesis￿, ￿mitogen-
activated protein kinase (MAPK) signaling pathway￿ and ￿cell cycle￿, respectively. ERBB2, TYMP, CDH1, TP53, DAPK1, CCND1, FGFR3, 
KRAS, E2F3, CDKN2A, VEGFA, MMP1 are the genes which are highly expressed in study when compared to control and these genes 
are associated with ￿ErbB signaling pathway￿, ￿nucleotide metabolism￿ ￿adherens junction￿, ￿p53 pathway￿, ￿cell cycle￿, ￿MAPK signaling 
pathway￿ and ￿angiogenesis￿. By this current pathway analysis approach to the GSE7476 bladder cancer datasets, we can say that genes 
like ERBB2, TYMP, CDH1, TP53, DAPK1, CCND1, FGFR3, KRAS, E2F3, CDKN2A, VEGFA, MMP1 can be used as prognosis mark-
ers for bladder cancer gene expression study. Association of above 12 sets of genes for causing cancer was confirmed from Online 
Mendelian Inheritance in Man (OMIM) and articles from PubMed database. Further research is needed to evaluate whether the same 
gene signatures result from other bladder cancer profiling experiments (Table 4).
Difference in expression level
Significant findings
According to KEGG pathway, ￿hsa05219￿ for bladder cancer, RB, CDKN2A and p53 are considered as tumour suppressor genes and 
FGFR3 and HRAS as oncogenes. Two of the tumour suppressor genes CDKN2A and p53 were expressed in significant level when com-
pared with normal tissue samples. FGFR3 which is an oncogene is highly expressed in tumour samples compared to control tissue sam-
ples. CDKN2A, p53 and FGFR3 along with the other genes ERBB2, TYMP, CDH1, DAPK1, CCND1, KRAS, E2F3, VEGFA and MMP1 are 
unregulated in tumour tissue samples. All these genes play an important role in ErbB signaling pathway, nucleotide metabolism, adherens 
Sl No Gene name Difference Pathways involved
1 THBS1 −2.07086 Angiogenesis
2 RPS6KA5 −1.43553 MAPK signaling pathway
3 CDKN1A −1.13441 Cell cycle
4 ERBB2 1.047714 ErbB signaling pathway
5 TYMP 1.114962 Nucleotide metabolism
6 CDH1 1.129588 Adherens junction
7 TP53 1.152218 p53 pathway￿tumour suppressor
8 DAPK1 1.243391 MAPK signaling pathway
9 CCND1 1.596004 Cell cycle
10 FGFR3 1.608031 MAPK signaling pathway
11 KRAS 1.789157 MAPK signaling pathway
12 E2F3 1.890258 Cell cycle
13 CDKN2A 2.116859 Cell cycle￿tumour suppressor
14 VEGFA 2.151066 Angiogenesis
15 MMP1 4.517153 Angiogenesis
MAPK, mitogen-activated protein kinase.
Table 3: List displaying up and downregulated genes, downregulated genes are marked in green colour and up regulated genes are marked in 
red colour with respect to tumour samplesecancer 2011, 5:189
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Gene name Diff (N−T2+) From reference article
THBS1 −2.070856 Not related to any cancer
RPS6KA5 −1.435529667 Not related to any cancer
CDKN1A −1.134411333 Cervical cancer
VEGFC −0.959871667 Gastric cancer
MYC −0.634828 Acute lymphoblastic leukaemia (ALL) (precursor B lymphoblastic leukaemia), ALL (precursor T lymphoblastic 
leukaemia ), Burkitt lymphoma, multiple myeloma, small cell lung cancer, oral cancer, penile cancer, ovarian 
cancer, choriocarcinoma, breast cancer, osteosarcoma, Kaposi￿s sarcoma, laryngeal cancer
RASSF1 −0.620339667 Non-small cell lung cancer, bladder cancer, nasopharyngeal cancer
VEGFB −0.586443667 Gastric cancer
MAPK1 −0.521910667 Not related to any cancer
FIGF −0.291046333 Gastric cancer
BRAF −0.233242333 Thyroid and malignant cancer
MAPK3 −0.168624 Not related to any cancer
DAPK2 −0.1407 Not related to any cancer
PGF −0.018144333 Not related to any cancer
MMP2 −0.004823 Choriocarcinoma
EGF 0.047375 Gastric cancer
RB1 0.057769667 Chronic myeloid leukaemia (CML), small cell lung cancer, oesophageal cancer, breast cancer, osteosarcoma, 
glioma, hepatocellular carcinoma
HRAS 0.090684333 Bladder, penile, cervical, thyroid cancer, squamous cell carcinoma, hepatocellular carcinoma
ARAF 0.161841333 Not related to any cancer
MAP2K2 0.169287667 Not related to any cancer
DAPK3 0.263293333 Not related to any cancer
IL8 0.273441 Not related to any cancer
RAF1 0.375785667 Not related to any cancer
MAP2K1 0.511718667 Not related to any cancer
E2F1 0.616598 Not related to any cancer
MMP9 0.674665 Penile cancer
EGFR 0.722004667 Oral cancer, oesophageal, gastric, bladder, cervical, laryngeal cancer, glioma and choriocarcinoma
E2F2 0.767106 Not related to any cancer
CDK4 0.892846333 Cervical cancer, malignant melanoma, glioma
NRAS 0.896107667 Acute myeloid leukaemia (AML), multiple myeloma, oral cancer, thyroid cancer, adrenal carcinoma, malignant 
melanoma, hepatocellular carcinoma, autoimmune lymphoproliferative syndromes
MDM2 0.922246667 Penile cancer, choriocarcinoma, osteosarcoma, alveolar rhabdmycosarcoma and glioma
ERBB2 1.047713667 Gastric, pancreatic, bladder, endometrial, ovarian, cervical, breast cancer, choriocarcinoma, cholangiocarcinoma
TYMP 1.114962333 Not related to any cancer
CDH1 1.129588 Gastric, penile, breast, thyroid, nasopharyngeal cancer and hepatocellular carcinoma
TP53 1.152217667 MAPK signaling pathway, cell cycle, p53 signaling pathway, apoptosis, Wnt signaling pathway, neurotrophin 
signaling pathway, amyotrophic lateral sclerosis, Huntington￿s disease, pathways in cancer, colorectal cancer, 
pancreatic cancer, endometrial cancer, glioma, prostate cancer, thyroid cancer, basal cell carcinoma, melanoma, 
bladder cancer, CML, small cell lung cancer, non-small cell lung cancer
DAPK1 1.243391333 Bladder cancer
CCND1 1.596003667 Hairy-cell leukemia, multiple myeloma, oral cancer, oesophageal cancer, breast cancer, laryngeal cancer
Table 4: Genes from the hsa05219 pathway involved in different cancers
Continuedwww.ecancermedicalscience.com 7
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junction, p53 pathway, MAPK signaling pathway, cell cycle and angiogenesis. THBS1, RPS6KA5 and CDKN1A are downregulated in 
tumour tissue when compared with control tissue samples. Out of the 42 genes listed in the KEGG bladder cancer pathway, only eight 
genes RASSF1, RB1, HRAS, EGFR, ERBB2, DAPK1, FGFR3 and CDKN2A have reference support to prove their involvement in causing 
bladder cancer. This current review suggest the lack of research/involvement of the other genes in the pathway to cause bladder cancer. 
Pathway analysis of affymetrix data file shows upregulation of four genes ERBB2, DAPK1, FGFR3 and CDKN2A which have reference to 
prove their involvement in causing bladder cancer.
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Table 4: Continued
Gene name Diff (N−T2+) From reference article
FGFR3 1.608030667 Multiple myeloma and bladder cancer
KRAS 1.789157
AML, multiple myeloma, non-small cell lung cancer, oral cancer, gastric cancer, pancreatic cancer, colorectal 
cancer, endometrial cancer, ovarian cancer, cervical cancer, thyroid cancer, squamous cell carcinoma, Kaposi￿s 
sarcoma, cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma
E2F3 1.890258333 Not related to any cancer
CDKN2A 2.116859
CML, Burkitt lymphoma, adult T-cell leukemia, non-small cell lung cancer, malignant pleural mesothelioma, 
oral cancer, oesophageal cancer, pancreatic cancer, bladder cancer, penile cancer, osteosarcoma, malignant 
melanoma, squamous cell carcinoma, glioma, malignant islet cell carcinoma, cholangiocarcinoma, gallbladder 
cancer, hepatocellular carcinoma, nasopharyngeal cancer, laryngeal cancer, type II diabetes mellitus
VEGFA 2.151066 Gastric cancer
MMP1 4.517153 Choriocarcinoma
Log difference between the control and study subjects which exceeds more than 1.0 or less than −1.0 were first screened. Downregulated genes are 
marked in green and upregulated genes are marked in red with respect to tumour samples.